Anjali Vaidya, MD: Expert Insights
- Patients with methamphetamine-associated pulmonary arterial hypertension (meth-PAH) often encounter important challenges, including delayed diagnosis, stigma, and a lack of integrated care, according to research presented at the 2025...
- The research involved interviews with meth-PAH patients across the U.S., revealing critical gaps in their clinical experiences.
- limited access to PAH specialists, mental health support, and substance use treatment also posed significant barriers.
Meth-PAH patients are frequently enough underserved, facing delayed diagnoses, stigma, and a lack of integrated care, according to research presented at the 2025 American Thoracic society International Conference, a study led by Dr. Anjali Vaidya. This groundbreaking research highlights the critical need for increased awareness and tailored care strategies for those with methamphetamine-associated pulmonary arterial hypertension. Findings reveal meaningful gaps in patient experiences, including insufficient education and limited access to PAH specialists and mental health support, making routine screening for methamphetamine use and enhanced physician education on this devastating disease essential. the research underscores the importance of integrating addiction care to improve patient outcomes, a finding that highlights the value of an empathy-driven approach. Discover how healthcare providers, including those reported on by News Directory 3, can better support this vulnerable population. Explore the implications of early detection and the innovative approaches to improved patient care.
Meth-PAH Patients Face Delayed Diagnosis, Lack of Support
Patients with methamphetamine-associated pulmonary arterial hypertension (meth-PAH) often encounter important challenges, including delayed diagnosis, stigma, and a lack of integrated care, according to research presented at the 2025 American thoracic Society International Conference. The study,led by Dr. anjali Vaidya of Temple University Hospital, highlights the urgent need for increased awareness and tailored care strategies for this vulnerable population.
The research involved interviews with meth-PAH patients across the U.S., revealing critical gaps in their clinical experiences. Vaidya’s team found that manny patients faced delayed diagnosis, were not routinely screened for methamphetamine use, and received insufficient education about their condition. Stigma surrounding substance use further complicated their clinical encounters.
limited access to PAH specialists, mental health support, and substance use treatment also posed significant barriers. However, patients reported higher satisfaction when treated by PAH-specific teams that fostered trust and open communication.
Vaidya emphasized the importance of routine methamphetamine screening,enhanced physician education,and integration with addiction care to improve outcomes for meth-PAH patients. She called on clinicians and healthcare systems to expand awareness, reduce stigma, and invest in tailored care strategies.
“Education for physicians who are likely to be the first point of contact for these patients—such as those in emergency medicine, primary care, hospital medicine, cardiology, and pulmonary specialties—is essential,” Vaidya said.
Vaidya noted that while the symptoms of meth-PAH are similar to other forms of PAH, the biological effects of methamphetamine on pulmonary circulation can be distinct. Treatment, therefore, must address both the cardiopulmonary effects and the substance use itself.
Social factors, such as insurance barriers and limited access to mental health care, also significantly impact outcomes. Patients often face hurdles in accessing specialized care and experience excessive wait times for appointments.
The study found that half of the patients began using methamphetamine between the ages of 18 and 25, with a quarter starting before age 18. Inhalation was the most common route of governance, but 40% reported ingestion, injection, or a combination of methods. most patients required combination medical therapy for PAH treatment.
To improve early detection of meth-PAH, Vaidya recommends integrating routine history taking and laboratory screening for methamphetamine use during initial evaluations for pulmonary hypertension.
“It is essential for PH specialists to work close with substance abuse specialists to provide truly comprehensive,supportive,and adequate care for these patients,” Vaidya said.
What’s next
the next steps involve increasing awareness among specialists who diagnose PAH, expanding access to substance abuse care, and strengthening education for patients around PAH management. this study underscores the urgent need for increased empathy, awareness, educational resources, and collaboration with substance abuse specialists in the care of meth-PAH patients.